Author’s response to reviews

Title: Development of a Disease-Specific Graded Prognostic Assessment index for the management of Sarcoma patients with Brain Metastases (Sarcoma-GPA).

Authors:

Anna Patrikidou (anna.patrikidou@hcahealthcare.co.uk; anna.patrikidou@sarahcannoresearch-co.uk)
Loic Chaigneau (lchaigneau@chu-besancon.fr)
Nicolas Isambert (NIisambert@cgfl.fr)
Kyriaki Kitikidou (kkitikid@fmenr.duth.gr)
Ryan Shanley (shan0219@umn.edu)
Isabelle Ray-Coquard (isabelle.ray-coquard@lyon.unicancer.fr)
Thibaud Valentin (valentin.thibaud@iuct-oncopole.fr)
Bettina Malivoir (B.MALIVOIR@chu-tours.fr)
Maryline Laigre (maryline.laigre@icm.unicancer.fr)
Jacques-Oliver Bay (jobay@chu-clermontferrand.fr)
Laurence Moureau-Zabotto (moureaul@ipc.unicancer.fr)
Emmanuelle Bompas (Emmanuelle.Bompas@ico.unicancer.fr)
Sophie Piperno-Neumann (sophie.piperno-neumann@curie.net)
Nicolas Penel (n-penel@o-lambret.fr)
Thierry Alcindor (thierry.alcindor@mcgill.ca)
Cecile Guillemet (cecile.guillemet@chb.unicancer.fr)
Florence Duffaud (florence.duffaud@ap-hm.fr)
Anne Hugli (annehugli@bluewin.ch)
Cecile Le Pechoux (cecile.lepechoux@gustaveroussy.fr)
Linda Gummlich
Editor
BMC Cancer

Dear Madam,

We are delighted to submit our revised manuscript entitled “Development of a Disease-Specific Graded Prognostic Assessment index for the management of Sarcoma patients with Brain Metastases (Sarcoma-GPA)”, revised according to reviewers’ comments and suggestions.

We thank all reviewers for their comments and the appreciation of the collaborative project effort, and the challenges involved. Please find below detailed consideration and responses to Reviewers comments:
Reviewer 2:

We have now added a supplementary table (Table S2) detailing the distribution of treatment modalities in the different histology groups, as requested by the reviewers, and statistically assessed their significance. Furthermore, we assessed the OS in the best prognostic groups (H4 and GPA4) according to treatment modality. Overall, the use of different treatment modalities, and notably local modalities known to be associated with better outcome in general (surgery, SRS) neither differed nor significantly influenced OS in the histology and GPA groups, which indicates that the better outcome of the H4 and GPA4 group was not influenced by a differential use of treatment modalities in these sub-groups, further strengthening the prognostic value of the index we describe in this paper.

Relevant references to the above have been made in the Results and Discussion sections.

All authors have approved the revised manuscript.

We thank you in advance for the time and effort in considering our work for publication.

Yours sincerely,

Anna Patrikidou

for the authors